Studies have found that people with migraines experience abnormalities during otoacoustic emission testing (OAE) and auditory brainstem evoked potential testing (ABR).This can also indicate that the patient has a potential hearing problem, which may further lead toHearing loss.
In addition, nearly two-thirds of migraine patients will have one or more abnormalities in the auditory electrophysiology-related functional tests, although most of them are ultimately judged to be normal hearing.The symptoms of auditory dysfunction include acoustic phobia (fear of loud noises) and tinnitus. The incidence of the two symptoms is 2% and 3%, respectively.
When migraine patients undergo transient evoked otoacoustic emissions (TEOAE) testing, the amplitude is significantly lower, with frequencies of 1 kHz, 3 kHz, and 4 kHz.
The amplitude of distortion product otoacoustic emission (DPOAE) detection in migraine patients was also significantly lower, with frequencies of 1 kHz, 2 kHz, 3 kHz and 5 kHz.
When the outer hair cells of the cochlea, which are responsible for amplifying the sound, react to the sound wave stimulus, they generate TEOAE and DPOAE test results.The process of cochlear outer hair cells in response to sound waves is called electrokinetic.
Sherifa Ahmad Hamed and colleagues at Asyut University Hospital in Egypt explained: “Otoacoustic reflex testing can assess the function of the cochlea before the occurrence of functional or more severe hearing loss, and the dynamic changes of the cochlear response. Objective monitoring.”
When migraine patients undergo high-frequency detection of auditory brainstem evoked potentials, the inter-peak latency of wave III and wave IV is prolonged, which also indicates that migraine patients have auditory central dysfunction.
The report was published in the American Journal of Otolaryngology.